Appco Company Profile
✉ Email this page to a colleague
What is the competitive landscape for APPCO
APPCO has twenty-five approved drugs.
There is one tentative approval on APPCO drugs.
Summary for Appco
| US Patents: | 0 |
| Tradenames: | 24 |
| Ingredients: | 24 |
| NDAs: | 25 |
| Patent Litigation for Appco: | See patent lawsuits for Appco |
Drugs and US Patents for Appco
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Appco | PRAZOSIN HYDROCHLORIDE | prazosin hydrochloride | CAPSULE;ORAL | 213406-002 | Oct 21, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Appco | RANITIDINE HYDROCHLORIDE | ranitidine hydrochloride | CAPSULE;ORAL | 211893-002 | Apr 5, 2019 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Appco | LABETALOL HYDROCHLORIDE | labetalol hydrochloride | TABLET;ORAL | 209603-001 | Jun 20, 2018 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Appco | HYDROCORTISONE | hydrocortisone | TABLET;ORAL | 220329-001 | Feb 25, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Appco | DOXEPIN HYDROCHLORIDE | doxepin hydrochloride | CAPSULE;ORAL | 214908-005 | Apr 1, 2021 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Appco | DOXEPIN HYDROCHLORIDE | doxepin hydrochloride | CAPSULE;ORAL | 214908-001 | Apr 1, 2021 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Appco | MODAFINIL | modafinil | TABLET;ORAL | 207196-002 | Aug 16, 2017 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

